(Q34225923)

31 July 2017

title

Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy (English)

1 reference

31 July 2017

Daniel M Moreira

1

0 references

author name string

Leah Gerber

2

1 reference

31 July 2017

Jean-Alfred Thomas

3

1 reference

31 July 2017

Lionel L Bañez

4

1 reference

31 July 2017

Madeline G McKeever

5

1 reference

31 July 2017

Stephen J Freedland

6

1 reference

31 July 2017

publication date

4 April 2012

1 reference

International Journal of Urology

31 July 2017

published in

1 reference

31 July 2017

volume

19

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

741-747

1 reference

Determining variables for repeat prostate biopsy

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Prostate-specific antigen doubling time as a prognostic marker in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

21 January 2018

Overdiagnosis in cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Repeat prostate biopsy: who, how and when?. a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Inherited genetic variant predisposes to aggressive but not indolent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

Evaluating localized prostate cancer and identifying candidates for focal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03016.X

10.1111/J.1442-2042.2012.03016.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference